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A B S T R A C T
Background
This is an updated version of the Cochrane Review previously published in 2013.
Most people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30%
develop drug-resistant epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised
controlled trials (RCTs) of gabapentin, when used as an add-on treatment for drug-resistant focal epilepsy.
Objectives
To evaluate the efficacy and tolerability of gabapentin when used as an add-on treatment for people with drug-resistant focal epilepsy.
Search methods
For the latest update, we searched the Cochrane Register of Studies (CRSWeb, 20March 2018), which includes the Cochrane Epilepsy
Group’s Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid, 1946 to 20
March 2018), ClinicalTrials.gov (20 March 2018) and the World Health Organization International Clinical Trials Registry Platform
( ICTRP, 20 March 2018). We imposed no language restrictions.
Selection criteria
Randomised, placebo-controlled, double-blind, add-on trials of gabapentin in people with drug-resistant focal epilepsy.We also included
trials using an active drug control group or comparing different doses of gabapentin.
Data collection and analysis
For this update, two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following
outcomes: seizure frequency, seizure freedom, treatment withdrawal (any reason) and adverse effects. Primary analyses were intention-
to-treat. We also undertook sensitivity best-case and worst-case analyses. We estimated summary risk ratios (RR) for each outcome and
evaluated dose-response in regression models.
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Main results
We included 12 trials representing 2607 randomised participants.We combined data from six trials inmeta-analyses of 1206 randomised
participants. The overall RR for reduction in seizure frequency of 50% or more compared to placebo was 1.89 (95% confidence
interval (CI) 1.40 to 2.55; 6 trials, 1206 participants; moderate-quality evidence). Dose regression analysis (for trials in adults) showed
increasing efficacy with increasing dose, with 25.3% (19.3 to 32.3) of people responding to gabapentin 1800 mg compared to 9.7%
on placebo, a 15.5% increase in response rate (8.5 to 22.5). The RR for treatment withdrawal compared to placebo was 1.05 (95%
CI 0.74 to 1.49; 6 trials, 1206 participants; moderate-quality evidence). Adverse effects were significantly associated with gabapentin
compared to placebo. RRs were as follows: ataxia 2.01 (99% CI 0.98 to 4.11; 3 studies, 787 participants; low-quality evidence),
dizziness 2.43 (99% CI 1.44 to 4.12; 6 studies, 1206 participants; moderate-quality evidence), fatigue 1.95 (99% CI 0.99 to 3.82; 5
studies, 1161 participants; low-quality evidence) and somnolence 1.93 (99% CI 1.22 to 3.06; 6 studies, 1206 participants; moderate-
quality evidence). There were no significant differences for the adverse effects of headache (RR 0.79, 99% CI 0.46 to 1.35; 6 studies,
1206 participants; moderate-quality evidence) or nausea (RR 0.95, 99% CI 0.52 to 1.73; 4 trials, 1034 participants; moderate-quality
evidence). Overall, the studies were rated at low to unclear risk of bias due to information on each risk of bias domain not being
available. We judged the overall quality of evidence (using the GRADE approach) as low to moderate due to potential attrition bias
resulting from missing outcome data and imprecise results with wide confidence intervals.
Authors’ conclusions
Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy. However, the trials reviewed were of
relatively short duration and provide no evidence for the long-term efficacy of gabapentin beyond a three-month period. The results
cannot be extrapolated to monotherapy or to people with other epilepsy types.
P L A I N L A N G U A G E S U M M A R Y
Gabapentin as an add-on for drug-resistant focal epilepsy
Background
Epilepsy is a disorder where recurrent seizures are caused by abnormal electrical discharges from the brain. Evidence from randomised
controlled trials (well-designed clinical trials in which people are allocated at random to test a specific drug, treatment or other
intervention) are often used to examine how effective and safe antiepileptic medicines are in people who experience such seizures. This
review included 12 studies and data from 2607 people with focal seizures (seizures that occur in just one part of the brain).
Study characteristics
Data from six of the studies were combined in the analysis. All the participants (including adults and children) were previously taking
at least one antiepileptic medicine and all were continuing to have seizures. Either gabapentin (an antiepileptic medicine) or a placebo
(a tablet that contains no medicine) was added to the medicine regimen.
Key results
The results showed that gabapentin effectively reduced seizureswhenused as an additional treatment.Compared to a placebo, gabapentin
was almost twice as likely to reduce seizures by 50% or more. The most common side effects associated with gabapentin ware ataxia
(poor co-ordination and unsteady gait), dizziness, fatigue and drowsiness.
Quality of the evidence
Overall the quality of evidence was low to moderate as information was not reported for all participants in some of the trials and some
of the results were imprecise. Research is needed into the effects of the long-term use of gabapentin.
The evidence is current to 20 March 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Gabapentin versus placebo for people with drug- resistant focal epilepsy
Patient or population: people with drug-resistant focal epilepsy
Settings: outpat ient
Intervention: gabapent in
Comparator: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Gabapentin
Reduction in seizure
frequency of ≥ 50%:
primary analysis
Number of seizures re-
ported in seizure diary
Follow-up: 12 to 14
weeks
12 per 100 23 per 100
(17 to 31)
RR 1.89
(95%CI 1.40 to 2.55)
1206
(6 studies)
⊕⊕⊕©
Moderatea
RR > 1 indicated out-
come was more likely in
gabapent in group
Treatment withdrawal
Number of part icipants
withdrawn for any rea-
son
Follow-up: 12 to 14
weeks
10 per 100 11 per 100
(8 to 15)
RR 1.05
(95%CI 0.74 to 1.49)
1206
(6 studies)
⊕⊕⊕©
Moderatea
RR > 1 indicated out-
come was more likely in
gabapent in group
Adverse effects: ataxia
Number of part icipants
experiencing ataxia
Follow-up: 12 to 14
weeks
5 per 100 10 per 100
(5 to 20)
RR 2.01
(99%CI 0.98 to 4.11)
787
(3 studies)
⊕⊕©©
Lowb,c
RR > 1 indicated out-
come was more likely in
gabapent in group
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Adverse effects: dizzi-
ness
Number of part icipants
experiencing dizziness
Follow-up: 12 to 14
weeks
6 per 100 14 per 100
(8 to 23)
RR 2.43
(99%CI 1.44 to 4.12)
1206
(6 studies)
⊕⊕⊕©
Moderatea
RR > 1 indicated out-
come was more likely in
gabapent in group
Adverse effects: fa-
tigue
Number of part icipants
experiencing fat igue
Follow-up: 12 to 14
weeks
4 per 100 7 per 100
(3 to 13)
RR 1.95
(99%CI 0.99 to 3.82)
1161
(5 studies)
⊕⊕©©
Lowa,d
RR > 1 indicated out-
come was more likely in
gabapent in group
Adverse effects: nau-
sea
Number of part icipants
experiencing nausea
Follow-up: 12 to 14
weeks
7 per 100 7 per 100
(4 to 12)
RR 0.95
(99%CI 0.52 to 1.73)
1034
(4 studies)
⊕⊕⊕©
Moderatea
RR > 1 indicated out-
come was more likely in
gabapent in group
Adverse effects: som-
nolence
Number of part icipants
experiencing somno-
lence
Follow-up: 12 to 14
weeks
7 per 100 14 per 100
(9 to 23)
RR 1.93
(99%CI 1.22 to 3.06)
1206
(6 studies)
⊕⊕⊕©
Moderatea
RR > 1 indicated out-
come was more likely in
gabapent in group
Adverse effects:
headache
Number of part icipants
experiencing headache
Follow-up: 12 to 14
weeks
8 per 100 6 per 100
(3 to 10)
RR 0.79
(99%CI 0.46 to 1.35)
1206
(6 studies)
⊕⊕⊕©
Moderatea
RR < 1 indicated out-
come was more likely in
control group.
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aDowngraded once for risk of bias: four studies had missing data and did not carry out intent ion-to-treat analysis. Best-case
and worst-case scenario analysis demonstrates that m issing data may have impacted on the size of the true treatment
ef fect
bDowngraded once for risk of bias: three studies had missing data and did not carry out intent ion-to-treat analysis.
cDowngraded once for imprecision: one study with small number of ef fects and wide conf idence intervals; concern regarding
the conf idence in overall ef fect.
dDowngraded once for imprecision: two studies with small-study ef fects and wide conf idence intervals; concern regarding
the conf idence in overall ef fect.
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B A C K G R O U N D
This is an updated version of the Cochrane Review previously
published in 2013 (Al-Bachari 2013).
The purpose of this updated Cochrane Review was to summarise
the current understanding of the role of gabapentin as an add-on
treatment in focal epilepsy resistant to at least one other antiepilep-
tic drug (AED).
Description of the condition
Epilepsy is a common neurological disorder characterised by re-
current seizures. Most people given a diagnosis of epilepsy have a
good prognosis and their seizures will be controlled by treatment
with a single AED (Reynolds 1981). However, up to 30% will
continue to have seizures despite treatment with adequate doses of
AEDs, often requiring treatment with a combination (Cockerell
1995). These people represent a significant therapeutic problem
taking into account that up to 2% to 3% of the population will ex-
perience epilepsy at some time in their lives (Hauser 1993).There
is no internationally accepted definition of drug resistance, so for
the purpose of this review, we considered people drug-resistant
if they had focal-onset seizures (simple focal or complex focal or
secondary generalised tonic-clonic seizures, or a combination of
these) and failed to respond to at least one monotherapy AED.
Description of the intervention
Although more than 12 new AEDs have entered the market since
1993, up to 30% of people remain refractory to current treat-
ments. Thus, a concerted effort continues to identify and develop
new therapies that will help these people (Barker-Haliski 2014).
Pharmacological treatment remains the first choice for controlling
epilepsy (Loscher 2002), although recent decades have seen ad-
vances in vagal stimulation (Panebianco 2015), and surgery (West
2015). Current first-line treatment for focal epilepsy includes:
lamotrigine, sodium valproate, carbamazepine, oxcarbazepine and
levetiracetam. When first-line medications fail to achieve seizure
freedom, add-on therapy is required.
How the intervention might work
Gabapentin was licensed for add-on use in the UK in 1993.
The mechanism of action of gabapentin is uncertain (McClean
1995). Gabapentin is a structural analogue of the neurotransmit-
ter gamma-aminobutyric acid (GABA). However, it does cross the
blood brain barrier and its activities are believed not to be GABA-
related. Gabapentin has a high volume of distribution, is not sig-
nificantly protein-bound or metabolised, and does not induce or
inhibit hepatic enzymes; thus, it has minimal-to-no known inter-
actions with other AEDs.
Why it is important to do this review
In this review, we summarised evidence from randomised con-
trolled trials (RCTs) on the efficacy and tolerability of gabapentin
for people with drug-resistant focal epilepsy in order to aid clin-
ical decision-making when considering gabapentin as an add-on
treatment within this population.
O B J E C T I V E S
To evaluate the efficacy and tolerability of gabapentinwhen used as
an add-on treatment for people with drug-resistant focal epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
To be included in our review, studies had to meet all the following
criteria:
1. RCTs that used an adequate method of concealment of
randomisation (e.g. allocation of sequentially sealed packages of
medication, sealed opaque envelopes, telephone randomisation);
2. double-blind trials, in which both participant and clinician
treating or assessing outcome were blinded to treatment
allocated;
3. placebo-controlled or alternative AED or range of
gabapentin doses used as controls;
4. parallel-group or cross-over studies.
Types of participants
People of any age with drug-resistant focal epilepsy (i.e. experi-
encing simple focal, complex focal or secondary generalised tonic-
clonic seizures).
Types of interventions
1. The active treatment group received gabapentin in addition
to conventional AED.
2. The control group received matched placebo, different dose
of gabapentin or alternative AED in addition to conventional
AED.
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Types of outcome measures
Primary outcomes
Reduction in seizure frequency of 50% or more
We chose the proportion of people with a 50%or greater reduction
in seizure frequency in the treatment period compared to the pre-
randomisation baseline period as the primary outcome. This is
commonly reported in this type of study and can be calculated for
studies that do not report it from baseline seizure data.
Seizure freedom
The proportion of people with complete cessation of seizures dur-
ing the treatment period.
Secondary outcomes
Treatment withdrawal
We used the proportion of people having treatment withdrawn
during the treatment period as a measure of global effectiveness.
Treatment is likely to be withdrawn due to adverse effects, lack of
efficacy or a combination of both, and this is an outcome to which
the person makes a direct contribution. In trials of short duration,
it is likely that adverse effects will be the most common reason for
withdrawal.
Adverse effects
1. The proportion of people experiencing the following five
common and important adverse effects:
i) ataxia;
ii) dizziness;
iii) fatigue;
iv) nausea;
v) somnolence.
2. The proportion of people experiencing the five most
common adverse effects if different from a. to e. above.
Search methods for identification of studies
Electronic searches
Searches were run for the original review in 1998 and subsequent
searches were run in 2000, 2003, 2005, 2007, 2010, 2011, 2012,
2013, 2015, 2016 and March 2018. For the latest update, we
searched the following databases:
1. Cochrane Register of Studies (CRS Web, 20 March 2018),
which includes the Cochrane Epilepsy Group’s Specialized
Register and the Cochrane Central Register of Controlled Trials
(CENTRAL), using the strategy shown in Appendix 1;
2. MEDLINE (Ovid, 1946 to 20 March 2018) using the
strategy shown in Appendix 2;
3. ClinicalTrials.gov (20 March 2018) using the strategy
shown in Appendix 3;
4. World Health Organization International Clinical Trials
Registry Platform ( ICTRP, 20 March 2018) using the strategy
shown in Appendix 4.
There were no language restrictions.
Searching other resources
We reviewed the reference lists of included studies to search for
additional reports of relevant studies.
Data collection and analysis
Selection of studies
In the present update, two review authors (AC and MP) inde-
pendently assessed trials for inclusion. Any disagreements were
resolved by discussion; failing this, we sought an opinion from a
third author.
Data extraction and management
Two review authors (AC and MP) independently extracted the
following information for each trial using a data extraction sheet.
Any discrepancies between the extractions of the two review au-
thors were resolved by discussion.
Methodological/trial design
1. Method of randomisation and allocation concealment.
2. Method of double-blinding.
3. Whether any participants had been excluded from reported
analyses.
4. Duration of baseline period.
5. Duration of treatment period.
6. Dose(s) of gabapentin tested.
Participant/demographic information
1. Total number of participants allocated to each treatment
group.
2. Age/sex.
3. Number with focal/secondary generalised seizures.
4. Seizure types.
5. Seizure frequency during the baseline period.
6. Number of background drugs.
Parke Davis sponsored most trials; we asked them to confirm the
following information:
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1. method of randomisation;
2. total number randomised to each group;
3. number of participants in each group achieving a 50% or
greater reduction in seizure frequency per treatment group;
4. number of participants having treatment withdrawn post-
randomisation per treatment group;
5. for those excluded:
i) the reason for exclusion;
ii) whether any of those excluded completed the
treatment phase;
iii) whether any of those excluded had a 50% or greater
reduction in seizure frequency during the treatment phase.
Outcomes
We recorded the number of participants experiencing each out-
come (see Types of outcome measures) per randomised group.
We contacted authors of trials for any missing information.
Assessment of risk of bias in included studies
Two review authors (AC and MP) independently assessed the risk
of bias for each trial using the Cochrane ’Risk of bias’ tool as
described in the Cochrane Handbook for Systematic Reviews of In-
terventions Higgins 2011. We rated included studies as high risk,
low risk, or unclear risk on six domains applicable to RCTs: ran-
domisation method, allocation concealment, blinding methods,
incomplete outcome data, selective outcome reporting and other
sources of bias.
We outlined studies failing to meet the criteria to be included in
the meta-analysis in narrative form; statistics for those included in
the meta-analysis are outlined below.
Measures of treatment effect
We presented the outcomes as risk ratios (RR) with 95% or 99%
confidence intervals (CI).
Unit of analysis issues
We assessed cross-over studies to determine if they presented
suitable data to allow for inclusion in meta-analysis using either
’paired’ results adjusted for the cross-over design, or first period
results.
One cross-over trial did not provide suitable data for inclusion
in the meta-analysis, but was discussed in narrative form (Leach
1997).
Dealing with missing data
We sought any missing data from study authors. We carried out
intention-to-treat (ITT), best-case and worst-case analysis to ac-
count for any missing data (see Data synthesis).
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important participant factors among trials (e.g. age, seizure type,
duration of epilepsy) and trial factors (e.g. methods of randomisa-
tion and blinding, missing data). We examined statistical hetero-
geneity using a Chi2 test (P > 0.10) and the I2 statistic (Higgins
2011).
Assessment of reporting biases
Protocol versus full study
We requested all protocols from study authors to enable a com-
parison of outcomes of interest. We intended to investigate any
suspected outcome reporting bias using theORBITmatrix system
(Kirkham 2010).
Funnel plot
Reporting biases arise when dissemination of research findings is
influenced by the nature and direction of results (Higgins 2011).
We intended to use funnel plots for investigating reporting biases
when 10 or more studies were included in meta-analysis, with
awareness that they have limited power to detect small-study effects
and we planned to seek statistical advice on their interpretation.
For this review, we did not produce funnel plots for outcomes as
fewer than 10 studies were included in meta-analysis.
Data synthesis
We employed a fixed-effect meta-analysis to synthesise the data.
Comparisons we carried out included:
1. intervention group versus controls on seizure reduction;
2. intervention group versus controls on seizure freedom;
3. intervention group versus controls on treatment
withdrawal;
4. intervention group versus controls on adverse effects.
We performed separate comparisons for different types of control
group (i.e. placebo or active control group) and study character-
istics (i.e. cross-over designed trials) to ensure appropriate combi-
nation of data.
The preferred estimate was the Mantel-Haenszel RR. For the out-
comes reduction in seizure frequency of 50% of more and treat-
ment withdrawal, we used 95% confidence intervals (CIs). For
individual adverse effects we used 99% CIs to make an allowance
for multiple testing by using wider CIs. This is not a strict for-
mal adjustment, as the number of individual adverse effects is not
known in advance.
Our analyses included all participants in the treatment group to
which they had been allocated. For the primary efficacy outcome
(reduction in seizure frequency of 50% or more, we undertook
three analyses.
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1. Primary (ITT) analysis: participants not completing follow-
up or with inadequate seizure data were assumed to be non-
responders. To test the effect of this assumption, we undertook
the following sensitivity analyses:
i) worst-case analysis: participants not completing
follow-up or with inadequate seizure data were assumed to be
non-responders in the gabapentin group and responders in the
placebo group;
ii) best-case analysis: participants not completing follow-
up or with inadequate seizure data were assumed to be
responders in the gabapentin group and non-responders in the
placebo group.
Dose regression analysis
We examined dose-response relationships using logistic regression
(for the five adult trials) and calculated probabilities for the fol-
lowing for differing doses: the percentage of participants having a
50% response; and the difference in the percentage of participants
responding to each dose compared to placebo. A binary variable
was defined with value 0 if the response was less than 50% and
value 1 otherwise. We examined dose-response relationships using
logistic regression, in the framework of generalised linear models,
using the package GLIM, with this binary variable as the outcome
variable (McCullagh 1989). Trial effects (i.e. adjustment for trial
specific differences) were not included in the regression models as
it was generally not possible to do so as some doses are confounded
with trials; in other words, the dose was evaluated in only a single
trial. As none of the tests for heterogeneity reached a significance
level of less than 30%, it seemed reasonable to proceed without
trial effects.
Subgroup analysis and investigation of heterogeneity
We intended to investigate heterogeneity using subgroup analy-
sis of important participant factors among trials (e.g. age, seizure
type, duration of epilepsy if deemed appropriate. As no important
heterogeneity was identified in the meta-analyses in this review,
no subgroup analysis was conducted.
Sensitivity analysis
We intended to carry out sensitivity analysis if there were pecu-
liarities between study quality, characteristics of participants, in-
terventions and outcomes.
Summarising and interpreting results
Weused theGRADE approach, as outlined in theGRADEHand-
book (Schünemann 2013), to interpret findings, and GRADEpro
GDT software (which imports data from Review Manager 5 soft-
ware (GRADEproGDT 2015)), to create a ’Summary of findings’
table for the primary outcome (reduction in seizure frequency of
50%ormore) and secondary outcomes (treatmentwithdrawal and
adverse effects).
We created a ’Summary of findings’ table for the most important
comparison (gabapentin versus placebo). We did not create ’Sum-
mary of findings’ tables for other comparisons with only a single
study contributing to the comparison.
R E S U L T S
Description of studies
Results of the search
Updated searches conducted since 2013 revealed 107 records iden-
tified from the databases outlined in Electronic searches. After re-
moval of 15 duplicates, 92 records and were screened for inclusion
in the review. We excluded 84 clearly irrelevant records and as-
sessed eight full-text articles for eligibility. We identified one new
study in this review update (French 2016) but did not include it
in the meta-analyses as no other included studies compared the
AEDs considered in this study (see Figure 1).
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Figure 1. Study flow diagram. Date of search 20 March 2018. RCT: randomised controlled trial.
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Included studies
Overall, the review included 12 studies, six of which were in the
meta-analyses. The data from the six remaining studies were not
combined in meta-analyses due to the differences in comparisons
investigated.
Kwan 2000 and Shapiro 2000 papers are awaiting classification
as only abstracts were obtainable, therefore, it was not possible to
critique the study design (see Characteristics of studies awaiting
classification).
There were seven trials that compared gabapentin to a placebo
(Anhut 1994; Appleton 1999; Leach 1997; Sivenius 1991; UK
Gabapentin 1990; US Gabapentin 1993; Yamauchi 2006), two
trials that examined two different doses of gabapentin (Fisher
2001; Tomovic 1999), one trial that compared gabapentin to viga-
batrin (Lindberger 2000), one trial that compared gabapentin to
lamotrigine (Sethi 2002), and one trial that compared gabapentin
to pregabalin (French 2016). All participants had drug-resistant
focal epilepsy and were taking at least one monotherapy AED.
Pre-existing AED regimens remained unchanged throughout the
study period. All outcome measures included seizure reduction
and adverse effects.
One parallel trial had a 12-week pre-randomisation baseline pe-
riod and a 12-week treatment period of gabapentin 900 mg/day
(111 participants) or gabapentin 1200mg/day (52 participants) or
placebo (109 participants) (Anhut 1994). Study medication was
administered three times daily (TDS). Included participants had
a minimum of six focal seizures within the baseline period and
were aged 12 years or over. Women of childbearing potential on
adequate contraception and participants with additional seizure
types were also included in this study.
One multicentre parallel trial had three phases: six weeks of base-
line period, nine weeks of double-blind dose escalation phase
and 12 weeks of double-blind maintenance phase (French 2016).
There were two arms: 242 participants randomised to gabapentin
(300 mg/day, 600 mg/day, 1200 mg/day, 1500 mg/day and 1800
mg/day) and 242 participants randomised to active control (prega-
balin 150 mg/day, 300 mg/day, 450mg/day and 600 mg/day), but
482 participants (241 in gabapentin group and 241 in pregabalin
group) received intended treatment. Participants were adults aged
18 to 80 years. During the nine-week dose-escalation phase, the
minimum maintenance phase dose was gabapentin 1200 mg/day
and pregabalin 300 mg/day TDS. During the 21-week double-
blind phase of the study, the median doses were gabapentin 1500
mg/day and pregabalin 450 mg/day.
The baseline period in one parallel trial was six weeks with a
treatment period of 12 weeks (Appleton 1999). Gabapentin 600
mg/day to 1200 mg/day was administered TDS and was depen-
dent on the weight of the participant. One hundred and twenty-
eight participants received placebo and 119 participants received
gabapentin. Participants were children aged less than 12 years and
with a minimum of four seizures during the baseline period.
One cross-over trial was a placebo-controlled study that did not
have a pre-randomisation baseline period; however, all partici-
pants reported at least four seizures per month for the previ-
ous three months (Leach 1997). There were four treatment arms
(gabapentin 1200 mg/day, 1800 mg/day and 2400 mg/day, and
placebo each administered on a TDS basis). All participants re-
ceived all doses/placebo in a cross-over design with a four-week
washout period between each treatment period. The study re-
cruited 27 participants and analysed 23 participants.
One parallel trial had a baseline period of three months in which
adults with focal epilepsy experienced four or more seizures a
month (Sivenius 1991). Participants received either gabapentin
900 mg/day (16 participants), gabapentin 1200 mg/day (nine par-
ticipants) or placebo (18 participants). Treatment medication was
administered for 3 months.
One parallel trial had a three-month baseline period where par-
ticipants had at least one focal seizure per week (UK Gabapentin
1990). This study had a two-week initiation phase of gabapentin
600 mg/day or placebo administered TDS, after which 61 partic-
ipants began a 12-week treatment period of 1200 mg/day taken
TDS and 66 participants received placebo.
One parallel trial recruited 306 adults, randomising 53 partici-
pants to gabapentin 600 mg/day, 101 participants to gabapentin
1200 mg/day, 54 participants to gabapentin 1800 mg/day and 98
participants to placebo, all administered TDS for 12 weeks (US
Gabapentin 1993). The study implemented an initiation period
of two to three days of either gabapentin 300 mg/day or 600 mg/
day up to the required dose. The baseline period was three months
and included people who had a minimum of four focal seizures
per month.
One trial examining gabapentin versus placebo had a baseline pe-
riod of 12 weeks and included people who had a minimum of
eight focal seizures during baseline (Yamauchi 2006). Adults were
randomised into one of three treatment arms: gabapentin 1200
mg/day (86 participants), gabapentin 1800 mg/day (41 partici-
pants) and placebo (82 participants), taken TDS over 12 weeks.
Two RCTs were gabapentin dose trials that had no placebo group
(Fisher 2001; Tomovic 1999). Fisher 2001 compared slow initia-
tion (300 mg on day one, 600 mg on day two and then 900 mg/
day for five days) and rapid initiation of gabapentin (placebo for
the first two days followed by 900 mg/day for five days). Three
hundred and sixty participants were in the slow initiation group
and 360 participants were in the rapid initiation dose. There was
no baseline period; participants were required to have been tak-
ing at least one AED for one month prior to the study and were
considered to have inadequate seizure control as defined by the
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authors. Participants were aged 12 years or older. The trial period
was seven days. Tomovic 1999 compared gabapentin 900 mg/day
versus gabapentin 1200 mg/day administered TDS over 12 weeks.
There were nine participants in each group. There was no formal
baseline period; participants were considered to have unsatisfac-
torily controlled seizures while taking at least one first-line AED
for three months prior to the study, as defined by the authors.
One trial compared gabapentin to lamotrigine; it had an eight-
week baseline period (Lindberger 2000). All participants had tried
no more than two AED monotherapy regimens and were on one
AED at the time of study (this had to exclude phenytoin). The
study required a minimum seizure frequency of four seizures dur-
ing an eight-week baseline period and two or more seizures during
the last month. One hundred and two participants (aged 12 to
75 years) received either gabapentin or vigabatrin add-on treat-
ment. There was a flexible dosing regimen over the subsequent
24 weeks: gabapentin variable dose 1800 mg/day minimum, then
2400 mg/day and then a maximum of 3600 mg/day, increased ev-
ery eight weeks as tolerated. The vigabatrin initial dose was 1000
mg/day, then 2000 mg/day, then 4000 mg/day, increased in the
samemanner (as tolerated by adverse effects) and increased if com-
plete seizure freedom was not attained. The total trial period was
24 weeks; however, outcome measures were taken at eight weeks
(awaiting clarification from author).
One trial compared gabapentin to lamotrigine in participants
refractory to the maximum tolerated dose of carbamazepine
monotherapy, with a seizure duration of two years or less (Sethi
2002). Twenty-seven participants received gabapentin and 25 par-
ticipants received lamotrigine and were aged 10 to 60 years. Base-
line seizure frequency was at least four seizures despite treatment
(unclear overwhat time frame). The baseline periodwas time of en-
rolment. The trial period was 12 weeks. Treatment was gabapentin
300 mg on day one, 300 mg twice daily on day two and thereafter
an increment of 300 mg/day until seizures were controlled or toxic
effects appeared. Lamotrigine was started at 50 mg/day for two
weeks, then 50 mg twice daily for two weeks, then increased by
50 mg to 100 mg every two weeks until seizures were controlled
or there were toxic effects.
For further information on each trial, see the Characteristics of
included studies table.
Excluded studies
In this update, we excluded eight studies for the following reasons:
three were not RCTs (Arya 2013; Bodalia 2013; Ohtsuka 2014);
two did not enrol an eligible population (Jacoby 2015; Nonoda
2014); two studies did not include gabapentin as an add-on treat-
ment (Korean Gabapentin Study Group 2000; Semah 2014); and
one had no seizure data recorded (Crawford 1987).
The details of these studies are given in the Characteristics of
excluded studies table.
Risk of bias in included studies
See Figure 2 and Figure 3 for a summary of the ’Risk of bias’ in
each included study.We rated included studies as having low, high
or unclear risk of bias for six domains applicable to RCTs: ran-
domisation method, allocation concealment, blinding methods,
incomplete outcome data, selective outcome reporting and other
sources of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six studies did not describe the method of allocation concealment
(authors have been contacted but we have been unable to clarify)
and therefore we rated these as unclear in terms of bias (Appleton
1999; Leach 1997; Lindberger 2000; Sethi 2002; Tomovic 1999;
Yamauchi 2006). The other six studies achieved randomisation by
generating random lists using random permuted blocks and by
computer-generated randomisation; and concealed allocation by
dispensing sequentially numbered packages to each participant al-
located treatment; we rated these studies as low risk of bias (Anhut
1994; Fisher 2001; French 2016; Sivenius 1991; UK Gabapentin
1990; US Gabapentin 1993).
Blinding
In six studies, the means of blinding was unclear (Appleton 1999;
French 2016; Leach 1997; Sethi 2002; Tomovic 1999; Yamauchi
2006); there were no specific details regarding who was blinded
(i.e. participants, study personnel or outcome assessors). The re-
maining six studies achieved blinding by providing packaging and
tablets that were identical in appearance for the gabapentin and
placebo groups; and were at low risk of bias for this domain
(Anhut 1994; Fisher 2001; Lindberger 2000; Sivenius 1991; UK
Gabapentin 1990; US Gabapentin 1993).
Incomplete outcome data
We rated three studies as low risk of bias for attrition bias due to the
ITT analyses undertaken by the study authors (Appleton 1999;
French 2016; Lindberger 2000). Seven studies excluded partici-
pants from the study and analysis without providing reasons for
this; and therefore we rated these as high in terms of bias (Anhut
1994; Fisher 2001; Leach 1997; Tomovic 1999; UK Gabapentin
1990; US Gabapentin 1993; Yamauchi 2006). Two studies anal-
ysed results on an ’as treated’ basis, but did report attrition; and
were at unclear risk of bias for this domain (Sethi 2002; Sivenius
1991).
Selective reporting
We rated all included studies at low risk of bias for this domain
as there was no suspicion of selective outcome reporting bias: all
expected outcomes were reported in each of the publications. .
Other potential sources of bias
All trials included in this reviewwere sponsored byParkeDavis, the
manufacturers of gabapentin, apart fromSethi 2002 andTomovic
1999, and therefore, we rated all studies as having a high risk of
funding bias, but Sethi 2002 and Tomovic 1999 studies as having
a low risk for this domain. There was no evidence of further bias
in any of the included studies.
Effects of interventions
See: Summary of findings for themain comparisonGabapentin
versus placebo for people with drug-resistant focal epilepsy
Gabapentin versus placebo
Seven trials compared gabapentin to a placebo (Anhut 1994;
Appleton 1999; Leach 1997; Sivenius 1991; UK Gabapentin
1990; US Gabapentin 1993; Yamauchi 2006).
Reduction in seizure frequency of 50% or more
Given that all participants had drug-resistant focal epilepsy, it
seemed reasonable to combine results from the paediatric and adult
studies for an overall estimate (irrespective of dose). Data from
the paediatric study (Appleton 1999) could not be included in
dose regression models, as participants were not randomised to
a specific daily dose. Seven trials provided data for this outcome
(Anhut 1994; Appleton 1999; Leach 1997; Sivenius 1991; UK
Gabapentin 1990; US Gabapentin 1993; Yamauchi 2006). See
Figure 4 for forest plots. One trial was not suitable for inclusion in
the meta-analysis due to the cross-over design but was discussed
in narrative form below (Leach 1997).
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Figure 4. Forest plot of comparison: 1 Gabapentin versus placebo, outcome: 1.1 Reduction in seizure
frequency ≥ 50%.
Intention-to-treat analysis
An analysis pooling data from six studies showed no evidence of
heterogeneity (Chi2 = 3.90, P = 0.56, I2 = 0%). The overall RR
for reduction in seizure frequency of 50% or more was 1.89 (95%
CI 1.40 to 2.55; 1206 participants; moderate-quality evidence,
Analysis 1.1).
Best-case and worst-case scenarios
Chi2 tests for heterogeneity for a response to gabapentin indicated
no significant heterogeneity (best-case: P = 0.08; worst-case: P =
0.95). The overall RRs for 50% responders across all studies were
2.52 (95% CI 1.89 to 3.37) for best-case scenarios and 1.35 (95%
CI 1.04 to 1.76) for worst-case scenarios (Analysis 1.1).
For all three analyses, the results suggested a significant treatment
effect. However, there was a considerable difference between esti-
mates.
Dose-response regression
Intention-to-treat analysis
A linear dose-response model gave a good summary (for the five
adult trials) of the log odds of 50% response rate. After adjust-
ing for dose, there was no difference in estimated dose-response
between studies. The log odds of response increase by 0.19 (stan-
dard error of the mean (SEM) 0.045) for a 300 mg increase in
daily gabapentin dose. This is about a 20% increase in the odds of
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response with a 300 mg increase in gabapentin dose. The reduc-
tion in deviance due to dose was 19.1 on one degree of freedom,
and the residual deviance was 10.9 on 13 degrees of freedom. The
trial in children was not included, as the doses were prescribed to
achieve particular levels of milligrams per kilogram per day.
The results were summarised in the following tables:
• the estimated percentage of participants responding to each
gabapentin dose and the percentage difference in participants
responding to each gabapentin dose compared to placebo with
95% CI (ITT) (Table 1);
• the estimated percentage of participants responding to each
gabapentin dose and the percentage difference in participants
responding to each gabapentin dose compared to placebo with
95% CI (best-case) (Table 2);
• the estimated percentage of participants responding to each
gabapentin dose and the percentage difference in participants
responding to each gabapentin dose compared to placebo with
95% CI (worst-case) (Table 3);
In the best-case analysis, there was about a 30% increase in the
odds of response with a 300 mg increase in gabapentin dose and
in the worst-case analysis, there was about a 10% increase in the
odds of response with a 300 mg increase in gabapentin dose.
All three analyses (ITT, best-case and worst-case) showed a signif-
icant increase in therapeutic effect with increasing dose. However,
there was a striking difference in the proportion of responders es-
timated.
Seizure freedom
Only two trials comparing gabapentin to placebo reported seizure
freedom data (Appleton 1999; Yamauchi 2006).
Yamauchi 2006 reported no participants attaining seizure free-
dom, whereas Appleton 1999 reported 3/119 participants receiv-
ing gabapentin as seizure-free compared to 1/128 participants re-
ceiving placebo. Due to the very small numbers of participants
achieving seizure freedom in the two trials, the data is not com-
bined in meta-analysis
Treatment withdrawal
A Chi2 test of heterogeneity suggested no significant statistical
heterogeneity (Chi2 = 4.13, df = 4, P = 0.53, I2 = 0%). The overall
RR for withdrawal for any reason was 1.05 (95% CI 0.74 to 1.49;
1206participants;moderate-quality evidence, Analysis 1.2), hence
there was insufficient evidence to conclude that people were more
likely to withdraw from gabapentin than placebo, but there could
have been a substantial withdrawal rate.
Adverse effects
In addition to reports of ataxia, dizziness, fatigue, nausea and som-
nolence, headache was among the sixmost common adverse effects
was included in our analysis. There were significant differences
between gabapentin and placebo for the following adverse effects
(see Analysis 1.3): ataxia (RR 2.01, 99% CI 0.98 to 4.11; 3 RCTs;
787 participants; low-quality evidence); dizziness (RR 2.43, 99%
CI 1.44 to 4.12; 6 RCTs; 1206 participants; moderate-quality evi-
dence); fatigue (RR 1.95, 99%CI 0.99 to 3.82; 5 RCTs; 1161 par-
ticipants; low-quality evidence) and somnolence (RR 1.93, 99%
CI 1.22 to 3.06; 6 RCTs, 1206 participants; moderate-quality ev-
idence). There were no significant differences for headache (RR
0.79, 99% CI 0.46 to 1.35; 6 RCTs; 1206 participants; moderate-
quality evidence) or nausea (RR 0.95, 99% CI 0.52 to 1.73; 4
RCTs; 1034 participants; moderate-quality evidence).
Cross-over trial, not included in meta-analysis
One trial was not suitable for inclusion in the meta-analysis due
to the cross-over design and due to a lack of a pre-randomisation
baseline period and was discussed in narrative form (Leach 1997).
Reduction in seizure frequency of 50% or more and seizure
freedom
The cross-over trial evaluated 23/27 participants (although there
were six withdrawals, two participants withdrew sufficiently late
in the study to provide analysable data). Two participants achieved
total seizure control throughout the active treatment phase and
none in the placebo phase. For simple focal seizures, two partic-
ipants showed ’in excess’ of 50% reduction in seizure frequency.
The median monthly frequency for simple focal seizures was not
significantly reduced in the treatment group (P = 0.80). The study
reported complex focal seizures with secondary generalisation sep-
arately; 5/17 participants had in excess of 50% reduction in seizure
frequency (non-significant).
Treatment withdrawal
Six participants withdrew, five due to adverse effects (four while
receiving placebo, one while receiving gabapentin) and one of
whom withdrew consent to participate after the second visit. One
participant did not provide complete data for seizure frequency
and was withdrawn from the study.
Adverse effects
Nineteen (79%) participants reported 47 adverse effects with
gabapentin and 15 participants (63%) reported 30 adverse effects
with placebo. There was a statistically significant difference (P =
0.006) at gabapentin 2400 mg/day. The types of adverse effects
were not reported.
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Dose comparison trials with no placebo group
Two studies compared two dose regimens with no placebo (Fisher
2001; Tomovic 1999).
For one study, we sent a data extraction form to a translator
(Tomovic 1999). Our understanding is that the study combined
outcomes for the two treatment arms, thus a comparison between
the two treatment groups could not be made. Another study only
measured adverse effects at day two and day seven of a slow ini-
tiation regimen and a rapid initiation regimen; therefore, this is
presented narratively below (Fisher 2001).
Reduction in seizure frequency of 50% or more
In the Tomovic 1999 study, 13/18 (72.2%) participants experi-
enced 50% or greater reduction in seizures (two of whom achieved
a 100% reduction). Three participants had a 26% to 49% reduc-
tion in seizure frequency. Two participants had worse seizure con-
trol.
Fisher 2001 did not measure reduction in seizure frequency of
50% or more.
Seizure freedom
In the Tomovic 1999 studies 2/18 (11.1%) participants were
seizure-free during the treatment period; however, it was not re-
ported in which dose group this was achieved.
Fisher 2001 did not measure seizure freedom.
Treatment withdrawals
Tomovic 1999 did not report any treatment withdrawals.
Fisher 2001 reported only participants who had full exposure to
the study medication during the whole period of assessment (i.e.
details of withdrawals were not provided).
Adverse effects
Tomovic 1999 reported adverse effects in three participants, two
of whom had dizziness and one had excessive sleepiness (they were
excluded from the study, therefore, not included in the total num-
ber of participants). They also noted bulimia, tremor, diplopia,
headache, nausea and ataxia.
Fisher 2001 reported adverse effects on day three and day seven
of a slow and rapid initiation regimen of gabapentin. See Table 4
for the proportion of people with adverse effects with percentages.
There were no statistically significant differences between the two
dose regimens, apart from more dizziness in the rapid initiation
group compared to the slow initiation group at day three only.
In addition, Tomovic 1999 reported 24-hour electroencephalo-
gram (EEG) recordings pre- and postintervention and revealed a
reduction in total epileptiform discharges from 229.87 to 167.13.
Gabapentin versus vigabatrin
One study compared gabapentin versus vigabatrin (Lindberger
2000).
Reduction in seizure frequency of 50% or more and seizure
freedom
The study noted a reduction in seizure frequency of 50% or more
and seizure freedom in 27/50 participants (54%) in the gabapentin
group and 34/52 participants (56%) in the vigabatrin group (on
an ITT basis); the 95% CIs were wide and this was not deemed
statistically significant. The proportion of seizure-free participants
without adverse effects was 13/50 (26%) in the gabapentin group
and 18/52 (35%) participants in the vigabatrin group. This was
not statistically significant. The study measured an extra variable
of ’improvement rate’ (proportion of participants with 50% or
greater seizure reduction without adverse effects), which was 24/
50 (48%) participants in the gabapentin group and 29/52 (56%)
participants in the vigabatrin group. Thirteen out of 50 partici-
pants were seizure-free in the gabapentin group compared to 18/
52 participants in the vigabatrin group.
Treatment withdrawals
There were 14 withdrawals from the study as a result of adverse ef-
fects, seven in each group. In the gabapentin group theywere status
epilepticus, psychiatric problems, epigastric pain, diplopia, vertigo
and dizziness (three participants); in the vigabatrin group they
were depression, generalised seizure, rash, numbness and dizziness
(three participants).
Adverse effects
In the gabapentin group, three participants experienced serious ad-
verse effects which were status epilepticus, pyelonephritis and psy-
chiatric problems. In the vigabatrin group, four participants had
serious adverse effects, which were agitation, depression, weight
gain, mononucleosis and a secondary generalised seizure. Thirty-
eight (76%) participants in the gabapentin group and 45 (86.5%)
participants in the vigabatrin group experienced adverse effects of
any type. The five most common adverse effects were similar in
both groups (tiredness, dizziness, respiratory infection, headache
and diarrhoea). Specific proportions of individual adverse effects
were not provided.
Gabapentin versus lamotrigine
One trial compared gabapentin versus lamotrigine (Sethi 2002).
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Reduction in seizure frequency of 50% or more and seizure
freedom
There was a 50% or greater reduction in seizure frequency by
77.7% of participants in the gabapentin group and 92% of partici-
pants in the lamotrigine group (ITT analysis). There was complete
seizure control in 8/27 (29.6%) participants in the gabapentin
group; this was not specified in the lamotrigine group.
Treatment withdrawals
Sethi 2002 did not report any treatment withdrawals.
Adverse effects
Twenty-two out of 27 (81.5%) participants in the gabapentin
group and 18/25 (72%) participants in the lamotrigine group re-
ported adverse effects. The most common adverse effects were
neurotoxic: dizziness (gabapentin: 22.2%; lamotrigine: 28%),
diplopia (gabapentin: 11.11%; lamotrigine: 24%), weakness
(gabapentin: 14.8%; lamotrigine: 24%), headache (gabapentin:
25.9%; lamotrigine: 20%), drowsiness (gabapentin: 14.8%; lam-
otrigine: 12%), tiredness (gabapentin: 14.8%; lamotrigine: 4%),
amnesia (gabapentin: 11.11%; lamotrigine: 12%), tingling sen-
sation (gabapentin: 11.11%; lamotrigine: 0%) and anorexia
(gabapentin: 11.11%; lamotrigine: 8%).
There were no serious adverse effects in the gabapentin group.
In the lamotrigine group, there were two serious adverse effects
(Steven Johnson’s syndrome and anxiety neurosis (corresponding
with an increase in seizure frequency)). Therewas an increase in the
number of seizures in one participant receiving gabapentin 2400
mg/day. In the gabapentin group, there was a change of seizure
type from focal seizures to myoclonic jerks or atypical seizures
in five participants during treatment. In the lamotrigine group,
seizure type changed to atypical absence (two participants) and
pseudoseizures (two participants).
Additionally, the benefit of gabapentin was more pronounced in
participants with simple focal seizures with secondary generalisa-
tion than in participants with simple and complex focal seizures
without secondary generalisation, whereas all subtypes of epilepsy
responded similarly in the lamotrigine group.
Gabapentin versus pregabalin
One study compared gabapentin versus pregabalin (French 2016).
Reduction in seizure frequency of 50% or more and seizure
freedom
There was a reduction in seizure frequency of 50% or more in
140/240 (58.3%) participants in the gabapentin group and 134/
238 (56.3%) participants in the pregabalin groups (on an ITT
basis); the 95%CIs were wide and this was not deemed statistically
significant. The proportion of seizure-free participants was 62/
182 (34.1%) in the gabapentin group and 58/189 (30.7%) in the
pregabalin group; these were not statistically significant. The study
measured an extra variable of ’improvement rate’ (proportion of
participants with 75% or greater seizure reduction) and was 82/
240 (34.2%) participants in the gabapentin group and 80/238
(33.6%) participants in the pregabalin group.
Treatment withdrawals
There were 123 withdrawals for any reason from the study, and
31 due to adverse effects (16 in the gabapentin group and 15 in
the pregabalin group). In the gabapentin group, the adverse ef-
fects were status epilepticus, psychiatric problems, epigastric pain,
diplopia, vertigo and dizziness (three participants); in the vigaba-
trin group, they were depression, generalised seizure, rash, numb-
ness and dizziness (three participants).
Adverse effects
In the gabapentin group, 129/241 (53.5%) participants reported
adverse effects and, in the pregabalin group, 142/241 (58.9%)
participants reported adverse effects. Both groups had six (2.5%)
participants with serious adverse effects. The five most common
adverse effects were similar in both groups (somnolence, dizziness,
headache, increased weight and dry month).
D I S C U S S I O N
Summary of main results
The results of the overall efficacy analysis showed that gabapentin
reduced seizure frequency when used as an add-on AED in
people with drug-resistant focal epilepsy. Compared to placebo,
gabapentin was almost twice as likely to reduce seizures by 50%
or more, however there was considerable discrepancy between the
results of the ITT and best-case and worst-case analyses, hence
the ITT analyses need to be interpreted with some caution (see
Implications for research). The dose-response regression analysis
indicated increasing efficacy with increasing dose. Results sug-
gested that the therapeutic effect of gabapentin 600 mg/day, al-
though statistically significant, was small and 900 mg/day would
seem a better initial dose. In addition, there was no apparent
’plateau’ of therapeutic effects at the doses tested and it may well
be that optimal doses of gabapentin have not been tested.
This was also reflected to a much greater extent by the studies
described in narrative form. The Tomovic 1999 study comparing
gabapentin doses reported 72.2% of the 18 participants evaluated
as having a 50% or greater reduction in seizure frequency outcome
(compared to 16% to 22% taken from the studies comparing
gabapentin to placebo combined in meta-analysis) even though
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the demographics and treatment doses were comparable. Similarly,
the active control trials reported a 54% response rate in Lindberger
2000 (compared to vigabatrin), 58% response rate in French
2016 (compared to pregabalin) and 77% response rate in Sethi
2002 (compared to lamotrigine). This could potentially be due
to two key differences in methodology: the definition of ’drug-
resistant’ focal epilepsy and to the dosing regimens. Lindberger
2000 defined drug resistance as failure to respond to no more
than two AEDmonotherapy regimens and gabapentin was always
added tomonotherapy. Sethi 2002 only recruited people refractory
to carbamazepine monotherapy and 88% of participants in the
Tomovic 1999 study were taking one other AED only. As the
remaining studies used people with refractory focal seizures who
were established on one or two AEDs and stable doses (apart from
Appleton 1999 who allowed three AEDs), the populations are
likely to have a less refractory epilepsy. In addition, Lindberger
2000 andSethi 2002 used aflexible dosing regimen, allowingdoses
of gabapentin to be increased as tolerated. This high flexibility
made dose adjustments possible in response to a lack of seizure
control, with doses of gabapentin 3600 mg/day allowed. This may
be reflective of the increased efficacy of gabapentin at higher doses
yet this flexible dosing method did result in complexity when
interpreting the results as the final doses achieved to maintain
seizure control have not been specified. At the other end of the
spectrum in the Leach 1997 study, despite allowing doses of 2400
mg, only two out of 23 (8.7%) participants achieved 50% or
greater focal seizure control; this may be reflective of the small
sample size and the cross-over design. All participants received all
doses (1200 mg, 1800 mg and 2400 mg) with a washout period of
four weeks between doses; this dosing patternmay have influenced
the efficacy of gabapentin, which may have resulted in period and
carry-over effects.
Results for the outcome ’Treatment withdrawal’ suggested that
gabapentinwaswell tolerated, as therewas no significant difference
between gabapentin and placebo. However, the efficacy results
suggested that optimal doses of gabapentin may not have been
tested and it may well be that higher doses of gabapentin were less
well tolerated. With respect to adverse effects, dizziness, fatigue
and somnolence were significantly more likely to occur in the
gabapentin-treated group. There were insufficient data available
for this review to delineate the precise adverse effect profile of this
drug.
Overall completeness and applicability of
evidence
The studies reviewed were all of short duration and no conclusions
could be drawn regarding the long-term efficacy of gabapentin.
One trial recruited children only (Appleton 1999), and the esti-
mate for seizure reduction was low in that study. Caution is re-
quired when extrapolating the results of this trial to adults.
In terms of seizure subtypes, Sethi 2002 reported gabapentin’s
more pronounced effects on simple focal seizures and secondary
generalised as opposed to complex focal seizures. This is contrary
to the US Gabapentin 1993 study, which observed gabapentin to
be more efficacious in complex focal seizures. This review focused
on the use of gabapentin in drug-resistant focal epilepsy and the
results could not be generalised to add-on treatment in people with
generalised epilepsy. Likewise, no inference can be made about the
efficacy and tolerability of gabapentin when used as monotherapy.
The results of this review indicated that gabapentin was an effec-
tive add-on treatment.We found three head-to-head trials with no
study finding a significant difference between gabapentin and the
alternative AED (pregabalin, vigabatrin and lamotrigine respec-
tively) (French 2016, Lindberger 2000; Sethi 2002). As clinicians
are faced with an ever increasing number of AEDs to choose from,
more head-to-head trials are required to provide the evidence that
is needed to enable clinicians to make an evidence-based choice
between AEDs.
It still remains difficult to predict the differences between a rapid
and slow initiation of gabapentin, as the Fisher 2001 study only
observed the effects of rapid initiation on the first day of starting
the maximum dose and four days later. However, they did contact
participants for the subsequent two weeks to report any serious
outcomes. These have not been documented in the report, there-
fore it is difficult to extrapolate data beyond this period.
Quality of the evidence
Six out of the 12 studies used adequate methods of concealment of
randomisation. All trials were double-blind; however, often little
information was reported as to how personnel/outcome assessors
were blinded. For the studies included in the meta-analysis, apart
from Yamauchi 2006, published reports referred to their analyses
as being ITT, with 222 of the 1688 participants recruited excluded
from analyses. Reported analyses would perhaps be better called
’exploratory,’ as participants who had treatment withdrawn dur-
ing the treatment period and did not meet the original trial in-
clusion criteria were excluded from the reported analyses, despite
completing the treatment period with adequate seizure data.
Additional data, supplied by Parke Davis, revealed that 38 partic-
ipants did not complete the treatment phase and nine had inad-
equate seizure data recorded, hence the percentage reduction in
seizure frequency could not be calculated for 47 of these partici-
pants. The Yamauchi 2006 study stated that 19 participants were
not included in the study andprovided reasons for this. The French
2016 study stated that 123 participants withdrew for any reason.
Similarly, there was a high risk of attrition bias in the remaining
studies, which we discussed in narrative form (Fisher 2001; Leach
1997; Tomovic 1999), apart from the Lindberger 2000 study for
which analysis was completely ITT. The Sethi 2002 study did not
give any information related to dropouts and, therefore, the risk
was uncertain. Selective outcome reporting bias was unclear in
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Leach 1997, Lindberger 2000, Sethi 2002, and Tomovic 1999 as
they mentioned ’seizure activity recorded’ without details of the
methodology.
Overall the quality of evidence was low to moderate due to po-
tential attrition bias resulting from missing outcome data and im-
precise results with wide confidence intervals. Research is needed
into the effects of the long-term use of gabapentin.
Potential biases in the review process
There were discrepancies between study designs that may be re-
flected in the variability of the results.
Parke Davis sponsored most of trials included in this review, apart
from Sethi 2002 and Tomovic 1999. Pfizer Inc., the manufacturer
of gabapentin and pregabalin, funded one trial (French 2016).
Agreements and disagreements with other
studies or reviews
We found no reviews or published information on the use of
gabapentin as add-on therapy for refractory focal epilepsy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In people with drug-resistant focal epilepsy, gabapentin has effi-
cacy as an add-on treatment. Moderate-quality evidence from this
review suggests that a dose of 1800 mg/day will reduce seizure
frequency by at least 50% in 25.3% of people (95% confidence
interval 19.3% to 32.3%). Although our results suggest that 600
mg has a statistically significant effect on seizure frequency, that
effect is small and 900 mg/day would seem a more reasonable
initial dose. Regression analyses show no plateau of therapeutic
effect and it is likely that optimal doses need to be tested in a more
standardised manner and final doses provided so that such results
can be included in meta-analyses in the future. Doses of up to
2400 mg/day are currently recommended in the British National
Formulary.
Low- to moderate-quality evidence suggests that dizziness, fatigue
and somnolence occurs significantly more often with gabapentin
than placebo; although gabapentin is generally well tolerated.
Implications for research
The conduct of future ’add-on’ trials
The striking differences between the intention-to-treat, worst-case
and best-case analyses for 50% responder rates has important im-
plications for the conduct of further ’add-on’ studies. For the inten-
tion-to-treat analysis in this review, all participants lost to follow-
up or excluded from analyses due to inadequate seizure recording
were assumed to be ’non-responders.’ The best-case and worst-
case analyses, although representing the extreme, test the effect of
making that assumption. When large discrepancies are found, as
in this case, the accuracy of individual trials and hence this review
is challenged.
The main problem here is that participants having trial treatment
withdrawn are no longer followed up. This provides a data set
that allows an explanatory ’on treatment analysis,’ but precludes
a robust intention-to-treat analysis. To minimise this problem,
every attempt must be made to follow participants up, even if
trial treatment has been withdrawn. This provides the maximum
data set from which analyses other than intention-to-treat may be
undertaken.
Further evaluation of gabapentin as an antiepileptic
drug
To further evaluate the place of gabapentin in the armamentarium
of available antiepileptic drugs, further studies are required which
address the following:
1. the efficacy and tolerability of add-on doses higher than
1800 mg/day in people with drug-resistant focal epilepsy, in
clearly specified doses and a clarification as to maximum doses
achieved when flexible regimens are employed;
2. the long-term efficacy and tolerability of add-on gabapentin
beyond three months;
3. how gabapentin compares with other add-on treatments in
drug-resistant focal epilepsy;
4. the role of gabapentin in childhood epilepsies and
5. how gabapentin compares with other standard antiepileptic
drugs, such as sodium valproate, as monotherapy in generalised
epilepsy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anhut 1994
Methods Randomised, double-blind, placebo-controlled, parallel-group study (conducted at 24
centres in Europe, Canada, South Africa and Australia)
3 treatment arms: 1 placebo and 2 gabapentin
Prospective pre-randomisation baseline period: 12 weeks
Treatment period: 12 weeks
Participants All adults
Cross-continent study
Total randomised: 272; all with drug-resistant focal epilepsy
109 to placebo; 111 to gabapentin 900 mg; 52 to gabapentin 1200 mg
56% men
Age range: 12-67 years
Other AEDs: ≤ 2
Median baseline seizure frequency/28 days: 10.2 (range 0.5 to 634.3)
Interventions Gabapentin 900 mg/day
Gabapentin 1200 mg/day
Placebo
All tablets and packaging were identical in appearance
Outcomes Proportion with a 50% reduction in seizure frequency
Response ratio (= (T - B)/(T + B) where T = number of seizures during the treatment
period and B = number of seizure in the baseline period)
Adverse effects
Notes 27 participants excluded from published analyses: 10 from the placebo group; 15 from
the gabapentin 900 mg group; 2 from the gabapentin 1200 mg group
Additional unpublished data allowed the inclusion of participants excluded despite com-
pleting the treatment phase with adequate seizure data. The following participants con-
tributed to the best-case and worst-case sensitivity analyses in this review
Placebo: 7; gabapentin 900 mg: 9; gabapentin 1200 mg: 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random permuted blocks to generate se-
quence for randomisation
Allocation concealment (selection bias) Low risk Allocated sequentially, sealed, numbered
packages
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Anhut 1994 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Tablets and packaging identical in appear-
ance
Incomplete outcome data (attrition bias)
All outcomes
High risk ’As treated’ analysis. Disproportionate
numbers excluded across groups: 13 in
placebo: 17 in gabapentin 900 mg: 2 in
gabapentin 1200 mg, some excluded de-
spite completing treatment phase. Exclu-
sions not included in published analyses
Selective reporting (reporting bias) Low risk Seizure diary for all groups, same outcomes.
Published reports include all prespecified
expected outcomes
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
Appleton 1999
Methods Randomised, double-blind, placebo-controlled, parallel-group study (conducted at 54
centres in Europe, South Africa, and the US)
Prospective pre-randomisation baseline period: 6 weeks
Treatment period: 12 weeks
Participants All children
Cross-continent study. Total randomised 247; all with drug-resistant focal seizures (15%
to 16% had generalised seizures also)
128 to placebo; 119 to gabapentin
54% male
Age range: 3-12 years
Other AEDs: ≤ 3
Baseline seizure frequency per 28 days: median 26.7 (range 1.3 to 2893)
Interventions Gabapentin 600-1800 mg/day (equivalent to 23.2-35.3 mg/kg/day)
Placebo
Outcomes Proportion with a 50% reduction in seizure frequency
Response ratio
Adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Appleton 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not specified
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Study mentions double-blinding; no de-
tails
Incomplete outcome data (attrition bias)
All outcomes
Low risk All evaluated on an ITT basis
Selective reporting (reporting bias) Low risk Published reports include all prespecified,
expected outcomes
The parent/guardian and physician global
assessment of participant seizure frequency
and well-being
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
Fisher 2001
Methods Randomised, double-blind, placebo-controlled, parallel-group study in the US
No formal baseline period
Treatment period: 7 days
Participants Aged ≥ 12 years (range 12-82 years)
Multicentre study in the US
720 participants randomised. Initially 320 per dose initiation regimen. Finally, 280 slow
initiation regimen and 294 rapid initiation, after withdrawals and exclusions for not
fulfilling pre-protocol criteria
All participants with a recent history of focal seizures, with or without secondary gen-
eralisation with either inadequate seizure control on 1 or 2 anticonvulsants or had been
judged to be unable to tolerate therapeutic dosages of these drugs (reaching maximum
tolerated dose of ≥ 1 anticonvulsant)
280 slow initiation regimen, 294 rapid initiation regimen
Slow initiation; 44.6% male, rapid initiation: 44.2% male
Interventions Slow initiation: 300 mg day 1, 600 mg day 2, then 900 mg/day
Rapid initiation: 2-day placebo lead-in followed by 900 mg/day
Total evaluated treatment period: 7 days
Outcomes Reports of fatigue, dizziness, somnolence and ataxia
Notes Study did not have a baseline period and only measured adverse outcomes over a 7-day
period (day 3 (equivalent to 3rd day of active study medication for slow initiation group
and first day for rapid initiation group) and day 7)), therefore unable to include in meta-
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Fisher 2001 (Continued)
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation schedule that assigned each
participant number to either the slow
group or the rapid group in a one-to-one
manner
Allocation concealment (selection bias) Low risk Number-specific blister packs
Blinding (performance bias and detection
bias)
All outcomes
Low risk Matching placebo, all participants had a 2-
day lead-in phase that was unknown to in-
vestigator and participant
Incomplete outcome data (attrition bias)
All outcomes
High risk Per-protocol analysis stated to include par-
ticipantswhomet the criteria for evaluation
(not ITT analysis). 781 enrolled, only 574
analysed for 3 reasons: inadequate meth-
ods, inadequate reasons and reasons for
withdrawal
Selective reporting (reporting bias) Low risk Appeared all expected and prespecified out-
comes were reported
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
French 2016
Methods Randomised, flexible dose, double-blind, parallel-group study
2 active treatment arms: 1 gabapentin and 1 pregabalin
Multicentre study: 56 centres (Eastern and Western Europe, Asia South and Central
America)
3 main phases: 6 weeks of baseline (screening), 9 weeks of double-blind dose escalation
(titration) and 12 weeks of double-blind maintenance phase (21-week treatment phase)
Participants Adults with refractory focal epilepsy
Inclusion criteria: aged 18-80 years; diagnosis of epilepsy with focal-onset seizures, inad-
equately controlled with ≤ 2 to≥ 5 prior AEDs, receiving 1 or 2 standard AEDs (other
than gabapentin or pregabalin), with a minimum of 4 focal-onset seizures during the 6-
week baseline phase with no 28-day focal-onset-seizure-free period
561 participants screened and 484 randomised: 242 to gabapentin and 242 to pregabalin
Number of people who received intended treatment: 241 gabapentin and 241 pregabalin
Number of people who completed the maintenance phase of the study: 172 gabapentin
(69 discontinued treatment) and 187 pregabalin (54 discontinued treatment)
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French 2016 (Continued)
Age (mean): gabapentin 35.3 (SD 12.9) years; pregabalin 34.9 (SD 13.0) years
Age at epilepsy diagnosis (mean): gabapentin 19.9 years; pregabalin 19.8 years
Time since diagnosis of epilepsy: gabapentin 15.8 years; pregabalin 15.6 years
Sex of participants: gabapentin 130 men and 111 women; pregabalin 127 men and 114
women
Interventions Intervention (241 participants): gabapentin (300 mg/day, 600 mg/day, 1200 mg/day,
1500 mg/day, 1800 mg/day);
Active control (241 participants): pregabalin (150 mg/day, 300 mg/day, 450 mg/day,
600 mg/day)
During the 9-week dose-escalation phase the minimum maintenance phase dose was
gabapentin 1200 mg/day and pregabalin 300 mg/day TDS. During the 21-week double-
blind phase of the study, the median doses were gabapentin 1500 mg/day and pregabalin
450 mg/day
Outcomes Seizure frequency: ≥ 50% reduction of seizures; ≥ 75% reduction of seizures
Seizure freedom (for final 28 days)
Withdrawals: any reasons and due to adverse effects
Adverse effects (more common): somnolence, dizziness, headache, increased weight and
dry mouth
Notes Clinical Trials.gov ID NCT00537940
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
method used
Allocation concealment (selection bias) Low risk Randomised participants to either
gabapentin or pregabalin (1:1)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details provided regarding blinding of
study personnel, participants and outcome
assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 242 participants allocated to gabapentin;
241 received treatment; 172 completed
maintenance phase; 69 participants with-
drew
242 participants allocated to pregabalin al-
location; 241 received treatment; 187 com-
pleted maintenance phase; 54 participants
withdrew
The reasons for exclusion were reported.
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French 2016 (Continued)
Selective reporting (reporting bias) Low risk Protocol unavailable to check a priori out-
comes, but appeared all expected and pre-
specified outcomes were reported
Other bias High risk Study funded by Pfizer Inc., the manufac-
turer of gabapentin and pregabalin
Study appeared free of other sources of bias
Leach 1997
Methods Double-blind, random order, cross-over, placebo-controlled study in the UK
12 weeks’ treatment or placebo
No baseline period, however all participants reported at least 4 seizures/month for 3
months and AED doses had remained unchanged for ≥ 3 months prior to study
Participants Single centre (Western Infirmary in Glasgow, UK)
Adults with focal seizures refractory to 1 or 2 AEDs
Total randomised: 27 participants; 23 analysed after withdrawals
Aged 16-67 years, mean 28.4 years
37% men prior to withdrawals
Interventions 3 sequential doses of gabapentin 400 mg, 600 mg and 800 mg TDS, each dose increase
after 4 weeks)
Placebo
Outcomes Seizure frequency
Seizure freedom
Adverse effects (scored, individual adverse effects not mentioned)
Neuropsychological tests (psychomotor, memory, cognition, dysphoria, temper, fatigue,
worry, tiredness)
Notes No baseline period, therefore not included in meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of randomisation provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind and matched placebo but no
further details provided
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Leach 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 25% of participants excluded and not anal-
ysed on an ITT basis
Selective reporting (reporting bias) Low risk Included all prespecified expected out-
comes
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
Lindberger 2000
Methods Randomised, double-blind, dose titration study comparing gabapentin with vigabatrin
(Denmark, Finland, Iceland, Norway and Sweden)
8-week baseline period, 24-week treatment period, evaluation period at 8 weeks com-
pared with baseline
To allow flexibility, this was a dose adjustment regimen, with increases in doses of drug
based onparticipant tolerance and seizure control, increased if required at 4-week periods,
with a maximum treatment period at each dose of 8 weeks
Participants Multicentre in 34 Nordic countries
102 participants randomised, then 35 (gabapentin group) and 44 (vigabatrin group)
post exclusions for not for fulfilling criteria
People with focal epilepsy who had tried no more than 2 AED monotherapy regimens
Interventions Gabapentin: variable dose 1800 mg/day minimum, then 2400 mg then maximum 3600
mg/day, increased every 8 weeks as tolerated
Vigabatrin: initial 1000 mg then 2000 mg then 4000 mg increased in the same manner
as gabapentin
Outcomes Primary outcome: improvement rate: proportion of participants with 50% seizure re-
duction without adverse effects
Seizure reduction rate: proportion of participants with 50% seizure reduction irrespective
of adverse effects
Responder rate: proportion of seizure-free participants without adverse effects
Secondary outcomes: quality of life measures, adverse effects, perimetry
Notes Results provided did not indicate the doses the participants had achieved of each drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk No details provided
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Lindberger 2000 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy technique, participants
received active drug and corresponding
placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed on an ITT basis
Selective reporting (reporting bias) Low risk Seizure activity reported
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
Sethi 2002
Methods Randomised control trial in India
Head-to-head trial; 2 treatment groups gabapentin and lamotrigine
Treatment period: 12 weeks
No formal baseline period (however, all had≥ 4 seizures, unclear over what time, despite
treatment with maximum dose carbamazepine monotherapy)
Participants 52 children and adults
Indian study
Refractory focal seizures
48% male
27 gabapentin (19 male: 8 female), 25 lamotrigine (6 male: 19 female)
Aged 10-60 years
Interventions Gabapentin: 300 mg day 1, 300 mg twice daily day 2, there after an increment of 300
mg daily until ≥ 50% reduction in seizures or toxic effects
Lamotrigine: 50 mg/day for 2 weeks, increased to 50 mg twice daily, subsequently an
increase of 50-100 mg daily until above criteria met
Outcomes Efficacy: seizure frequency, pattern of seizures, seizure-free interval. Including % change
of seizure frequency from baseline, responder rate (reduction in seizure frequency of ≥
50%), response ratio
Safety: biochemical investigations and adverse effects
Notes As no clear baseline period, excluded from meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
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Sethi 2002 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No participants seemed to be excluded
from the results, but 1 participant in
gabapentin group did not seem to be ac-
counted for
Selective reporting (reporting bias) Low risk Included all prespecified expected out-
comes
Other bias Low risk Study appeared free of other sources of bias
Sivenius 1991
Methods Randomised, double-blind, placebo-controlled, parallel-group study in Finland
3 treatment arms: 1 placebo and 2 gabapentin
Prospective pre-randomisation baseline period: 12 weeks
Treatment period: 12 weeks
Participants All adults
Total randomised: 45 participants; all with drug-resistant focal epilepsy
18 placebo; 18 gabapentin 900 mg/day; 9 gabapentin 1200 mg/day
47% men
Aged 16-59 years
Other AEDs: ≤ 2
Median baseline seizure frequency per 12-week baseline period: 36 placebo; 26
gabapentin 900 mg/day; 23 gabapentin 1200 mg/day
Interventions Gabapentin 900 mg/day
Gabapentin 1200 mg/day
Placebo
All treatments and packaging were identical in appearance
Outcomes Median change in seizure frequency
% change in seizure frequency
Adverse effects
Notes 2 people in the gabapentin 900 mg group were excluded from analysis, both excluded 2
weeks’ postrandomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocated sequentially, sealed, numbered
packages
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Sivenius 1991 (Continued)
Allocation concealment (selection bias) Low risk Random permuted blocks
Blinding (performance bias and detection
bias)
All outcomes
Low risk Tablets and packaging identical in appear-
ance. Identical analysis of results
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No reasons reported for exclusion of 2 par-
ticipants in gabapentin 900 mg group
Selective reporting (reporting bias) Low risk Quote: “... seizure frequency was recorded”
Unclear how, otherwise included all pre-
specified expected outcomes
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
Tomovic 1999
Methods Randomised, parallel-group study in Serbia
Participants 9 women and 9 men with refractory focal epilepsy. Serbian adults
Mean age: 24.7 years, range 17-47 years
Drug-resistant focal epilepsy
All had been treated with 1 or 2 first-line AEDs during 3 months before introducing
gabapentin with unsatisfactorily controlled seizures
Seizure frequency prior to treatment was unclear
Interventions Gabapentin 900 mg
Gabapentin 1200 mg
Outcomes Seizure frequency
Seizure freedom
Haematological and biochemical analyses (4th and 12th week) and 24-hour EEG on
before therapy and on final week (week 12). Frequency of epileptiform discharges noted
Reduction in seizure activity: 26%-49%; 50-99%; 100%; worse state
Adverse effects
Notes 3 people did not complete the study and were not included in the study altogether (i.e.
not included in demographics, etc.)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation unclear
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Tomovic 1999 (Continued)
Allocation concealment (selection bias) Unclear risk How participants allocated to each group
unclear
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Unclear if tablets and packaging identical
in appearance
Incomplete outcome data (attrition bias)
All outcomes
High risk Unclear why 3 participants dropped out
and excluded from analysis
Selective reporting (reporting bias) Low risk Seizure frequency recorded; unclear how
seizure activity measured. Otherwise stan-
dardised tests for both groups
Other bias Low risk Study appeared free of other sources of bias
UK Gabapentin 1990
Methods Randomised, double-blind, placebo-controlled, parallel-group study (cross-continent)
Prospective pre-randomisation baseline period: 12 weeks
Treatment period: 14 weeks
Participants All adults
Cross-continent study
Total randomised: 127; all with drug-resistant focal epilepsy
Placebo: 66 participants; gabapentin 1200 mg/day: 61 participants
39% men
Age range: 14-73 years
Other AEDs: ≤ 2
Median baseline seizure frequency/28 days: gabapentin 13 (range 3 to 368); placebo 13
(range 1 to 216)
Interventions Gabapentin 1200 mg/day
Placebo
All treatments and packaging identical in appearance
Outcomes Proportion with a 50% reduction in seizure frequency
Response ratio
Adverse effects
Notes 14 participants excluded from published analyses: 5 from the placebo group; 9 from the
gabapentin 1200 mg/day group
Additional unpublished data allowed the inclusion of participants excluded despite com-
pleting the treatment phase with adequate seizure data. The following participants con-
tribute to the best-case and worst-case sensitivity analyses in this review
Placebo: 2; gabapentin 1200 mg: 8
Risk of bias
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UK Gabapentin 1990 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random permuted blocks to generate
sequence for randomisation
Allocation concealment (selection bias) Low risk Allocated sequentially, sealed, numbered
packages
Blinding (performance bias and detection
bias)
All outcomes
Low risk Used tablets and packaging identical in ap-
pearance
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate reported, 14participantswho
withdrew were not included in published
analyses. Report withdrawals and gave rea-
sons for withdrawal
Selective reporting (reporting bias) Low risk Included all prespecified, expected out-
comes
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
US Gabapentin 1993
Methods Randomised, double-blind, placebo-controlled, parallel-group study in the US
4 treatment arms: 1 placebo and 3 gabapentin
Prospective pre-randomisation baseline period: 12 weeks
Treatment period: 12 weeks
Participants All adults
USA study
Total randomised: 306 participants; all with drug-resistant focal epilepsy
Placebo: 98 participants; gabapentin 600 mg/day: 53; gabapentin 1200 mg/day: 101;
gabapentin 1800 mg/day: 54
66% men
Aged 16-70 years
Other AEDs: ≤ 2
Median baseline seizure frequency/28 days: 10.8 (range 2.0-1092.7)
Interventions Gabapentin 600 mg/day
Gabapentin 1200 mg/day
Gabapentin 1800 mg/day
Placebo
All treatments and packages were identical in appearance
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US Gabapentin 1993 (Continued)
Outcomes Proportion with a 50% reduction in seizure frequency
Response ratio
Adverse effects
Notes 18 participants excluded from published analyses: placebo: 3; gabapentin 600 mg/day:
4; gabapentin 1200 mg/day: 10; gabapentin 1800 mg/day: 1
Additional unpublished data allowed the inclusion of participants excluded despite com-
pleting the treatment phase with adequate seizure data. The following participants con-
tribute to the best-case and worst-case sensitivity analyses in this review. Placebo: 2;
gabapentin 600 mg/day: 4; gabapentin 1200 mg/day: 10; gabapentin 1800 mg/day: 1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random permuted blocks to generate
sequence for randomisation
Allocation concealment (selection bias) Low risk Allocated sequentially, sealed, numbered
packages
Blinding (performance bias and detection
bias)
All outcomes
Low risk Used tablets and packaging identical in ap-
pearance
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate reported, 18 participants not
included in published analyses and no rea-
sons given
Selective reporting (reporting bias) Low risk Included all prespecified expected out-
comes
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
Yamauchi 2006
Methods Randomised, double-blind, placebo-controlled, parallel-group study in Japan
Prospective pre-randomisation baseline period: 12 weeks
Treatment period: 12 weeks
Dose-reduction period lasting 8 days, 4 weeks instituted, followed by a 4-week post-
dosing observation period
3 treatment arms, 1 placebo and 2 treatment
Participants Adults aged ≥ 16 years
Most aged 18-44 years, mean age between 3 groups 31-33 years
Multicentre Japanese study from March 2000 to October 2002
Other AEDs: > 1
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Yamauchi 2006 (Continued)
Total randomised 209 participants; all with drug-resistant focal epilepsy
82 participants to placebo (42 men, mean age: 31.8 (SD 11.3) years, 25 secondary
generalised seizures, mean duration epilepsy: 19.5 years, mean seizure frequency/28 days:
19.9, 1 other AED: 19.5%, 2 other AEDs: 80.5%)
86 participants to gabapentin 1200 mg (37 men, mean age 31.3 (SD 10.6) years, 26.
3 secondary generalised seizures, mean duration epilepsy: 19.8 years, mean seizure fre-
quency/28 days: 31.6, 1 other AED: 14%, 2 other AEDs: 86%)
41 participants to gabapentin 1800 mg (22 men, mean age 32.7 (SD 13.7) years, 13 sec-
ondary generalised seizures, mean duration epilepsy: 21.2 years, mean seizure frequency/
28 days: 24.2, 1 other AED: 4.9%, 2 other AEDs: 95.1%)
19 excluded; after exclusion placebo: 75, gabapentin 1200 mg: 80, gabapentin 1800 mg:
35
Baseline seizure frequency/12 weeks: 8
Interventions Gabapentin 1200 mg/day
Gabapentin 1800 mg/day
Placebo
All treatments were identical in appearance (200 mg tablets)
Outcomes Improvement in seizure frequency: completely (-100%), markedly improved (-99.9% to
-75.0%), moderately improved (-74.9% to -50%), slightly improved (-49.9% to -25%)
, no change (-24.9% to 0%), aggravated (> +0.1%)
Response ratio (= (T - B)/(T + B) where T = number of seizures during the treatment
period, and B = number of seizure in the baseline period)
Seizure intensity/duration: better, no change and worse
Adverse effects
Serious treatment-related adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Little/no detail regarding randomisation
given. Most variables between groups con-
trolled (age, sex, frequency, number of
other AED, previous treatments etc.)
Allocation concealment (selection bias) Unclear risk Insufficient information provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Tablets identical in appearance, all out-
comes blinded, monitored and followed up
in the same way
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analysis not employed; reasons for ex-
clusions stated; however, 19 participants
not included
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Yamauchi 2006 (Continued)
Selective reporting (reporting bias) Low risk Seizure diary for all groups, same outcomes.
Published reports include all prespecified
expected outcomes
Other bias High risk Trial sponsored by Parke Davis
Study appeared free of other sources of bias
AED: antiepileptic drug; EEG: electroencephalogram; ITT: intention-to-treat; SD: standard deviation; TDS: three times daily.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arya 2013 Not an RCT
Bodalia 2013 Not an RCT
Crawford 1987 No seizure data recorded
Jacoby 2015 Ineligible population (new-onset epilepsy)
Korean Gabapentin Study Group 2000 No gabapentin in add-on (sodium valproate in add-on)
Nonoda 2014 Ineligible population (no refractory epilepsy)
Ohtsuka 2014 Not an RCT
Semah 2014 No gabapentin in add-on
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Kwan 2000
Methods Double-blind, randomised, placebo-controlled, cross-over study in China
Participants 43 adults with refractory focal seizures
Interventions Gabapentin 600 mg/day for 1 week and 1200 mg/day for 12 weeks with matching placebo controls
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Kwan 2000 (Continued)
Outcomes A statistically significant difference in seizure frequency from the baseline to the treatment phase was noted between
patients receiving placebo and GBP 1,200 mg, in whom seizure frequency decreased 57%. The GBP dosage of 900
mg appeared to be ineffective. A close relationship was observed between the serum GBP concentrations and the
GBP dosage based on the seizure frequency. Serum GBP concentrations greater than 2 micrograms/ml resulted in a
lower frequency of seizures
Notes No other data available for analysis; all data taken from abstract; author unable to provide further information
Shapiro 2000
Methods Randomised, placebo-controlled trial in US
Participants 76 young children with focal epilepsy
Interventions Syrup formulation of gabapentin 40 mg/kg/day given TDS or placebo
Outcomes Main outcome was seizure reduction. Concluded that gabapentin was safe and well tolerated, and reduced the rate
of focal seizures; however, this finding did not reach significance
Notes All information taken from abstract, unable to contact study authors
SD: standard deviation; TDS: three times daily.
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D A T A A N D A N A L Y S E S
Comparison 1. Gabapentin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in seizure frequency
≥ 50%
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Primary analysis 6 1206 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [1.40, 2.55]
1.2 Sensitivity (best-case) 6 1206 Risk Ratio (M-H, Fixed, 95% CI) 2.52 [1.89, 3.37]
1.3 Sensitivity (worst-case) 6 1206 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.04, 1.76]
2 Treatment withdrawal 6 1206 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.74, 1.49]
3 Adverse effects 6 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
3.1 Ataxia 3 787 Risk Ratio (M-H, Fixed, 99% CI) 2.01 [0.98, 4.11]
3.2 Dizziness 6 1206 Risk Ratio (M-H, Fixed, 99% CI) 2.43 [1.44, 4.12]
3.3 Fatigue 5 1161 Risk Ratio (M-H, Fixed, 99% CI) 1.95 [0.99, 3.82]
3.4 Headache 6 1206 Risk Ratio (M-H, Fixed, 99% CI) 0.79 [0.46, 1.35]
3.5 Nausea 4 1034 Risk Ratio (M-H, Fixed, 99% CI) 0.95 [0.52, 1.73]
3.6 Somnolence 6 1206 Risk Ratio (M-H, Fixed, 99% CI) 1.93 [1.22, 3.06]
Analysis 1.1. Comparison 1 Gabapentin versus placebo, Outcome 1 Reduction in seizure frequency ≥ 50%.
Review: Gabapentin add-on treatment for drug-resistant focal epilepsy
Comparison: 1 Gabapentin versus placebo
Outcome: 1 Reduction in seizure frequency≥ 50%
Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Primary analysis
Anhut 1994 36/163 11/109 22.1 % 2.19 [ 1.17, 4.11 ]
Appleton 1999 25/119 21/128 33.9 % 1.28 [ 0.76, 2.16 ]
Sivenius 1991 5/27 3/18 6.0 % 1.11 [ 0.30, 4.08 ]
UK Gabapentin 1990 13/61 6/66 9.6 % 2.34 [ 0.95, 5.78 ]
US Gabapentin 1993 39/208 8/98 18.2 % 2.30 [ 1.12, 4.73 ]
Yamauchi 2006 20/127 5/82 10.2 % 2.58 [ 1.01, 6.61 ]
Subtotal (95% CI) 705 501 100.0 % 1.89 [ 1.40, 2.55 ]
Total events: 138 (Gabapentin), 54 (Placebo)
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours gabapentin
(Continued . . . )
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(. . . Continued)
Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 3.90, df = 5 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 4.16 (P = 0.000032)
2 Sensitivity (best-case)
Anhut 1994 47/163 11/109 22.1 % 2.86 [ 1.55, 5.26 ]
Appleton 1999 25/119 21/128 33.9 % 1.28 [ 0.76, 2.16 ]
Sivenius 1991 7/27 3/18 6.0 % 1.56 [ 0.46, 5.24 ]
UK Gabapentin 1990 21/61 6/66 9.6 % 3.79 [ 1.64, 8.75 ]
US Gabapentin 1993 54/208 8/98 18.2 % 3.18 [ 1.58, 6.42 ]
Yamauchi 2006 32/127 5/82 10.2 % 4.13 [ 1.68, 10.17 ]
Subtotal (95% CI) 705 501 100.0 % 2.52 [ 1.89, 3.37 ]
Total events: 186 (Gabapentin), 54 (Placebo)
Heterogeneity: Chi2 = 9.68, df = 5 (P = 0.08); I2 =48%
Test for overall effect: Z = 6.26 (P < 0.00001)
3 Sensitivity (worst-case)
Anhut 1994 36/163 18/109 25.8 % 1.34 [ 0.80, 2.23 ]
Appleton 1999 25/119 21/128 24.2 % 1.28 [ 0.76, 2.16 ]
Sivenius 1991 5/27 3/18 4.3 % 1.11 [ 0.30, 4.08 ]
UK Gabapentin 1990 13/61 9/66 10.3 % 1.56 [ 0.72, 3.39 ]
US Gabapentin 1993 39/208 11/98 17.9 % 1.67 [ 0.89, 3.12 ]
Yamauchi 2006 20/127 12/82 17.4 % 1.08 [ 0.56, 2.08 ]
Subtotal (95% CI) 705 501 100.0 % 1.35 [ 1.04, 1.76 ]
Total events: 138 (Gabapentin), 74 (Placebo)
Heterogeneity: Chi2 = 1.16, df = 5 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.024)
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours gabapentin
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Analysis 1.2. Comparison 1 Gabapentin versus placebo, Outcome 2 Treatment withdrawal.
Review: Gabapentin add-on treatment for drug-resistant focal epilepsy
Comparison: 1 Gabapentin versus placebo
Outcome: 2 Treatment withdrawal
Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anhut 1994 11/163 9/109 19.8 % 0.82 [ 0.35, 1.91 ]
Sivenius 1991 2/27 0/18 1.1 % 3.39 [ 0.17, 66.79 ]
UK Gabapentin 1990 7/61 5/66 8.8 % 1.51 [ 0.51, 4.52 ]
US Gabapentin 1993 12/208 2/98 5.0 % 2.83 [ 0.65, 12.39 ]
Appleton 1999 21/119 28/128 49.6 % 0.81 [ 0.49, 1.34 ]
Yamauchi 2006 12/127 7/82 15.6 % 1.11 [ 0.45, 2.69 ]
Total (95% CI) 705 501 100.0 % 1.05 [ 0.74, 1.49 ]
Total events: 65 (Gabapentin), 51 (Placebo)
Heterogeneity: Chi2 = 4.13, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours gabapentin
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Analysis 1.3. Comparison 1 Gabapentin versus placebo, Outcome 3 Adverse effects.
Review: Gabapentin add-on treatment for drug-resistant focal epilepsy
Comparison: 1 Gabapentin versus placebo
Outcome: 3 Adverse effects
Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Ataxia
Yamauchi 2006 1/127 0/82 3.2 % 1.95 [ 0.03, 128.51 ]
Anhut 1994 13/163 3/109 18.8 % 2.90 [ 0.57, 14.62 ]
US Gabapentin 1993 42/208 11/98 78.1 % 1.80 [ 0.80, 4.06 ]
Subtotal (99% CI) 498 289 100.0 % 2.01 [ 0.98, 4.11 ]
Total events: 56 (Gabapentin), 14 (Placebo)
Heterogeneity: Chi2 = 0.46, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
2 Dizziness
Anhut 1994 30/163 9/109 31.8 % 2.23 [ 0.88, 5.62 ]
Sivenius 1991 2/27 1/18 3.5 % 1.33 [ 0.06, 28.32 ]
UK Gabapentin 1990 4/61 3/66 8.5 % 1.44 [ 0.21, 9.78 ]
US Gabapentin 1993 48/208 9/98 36.1 % 2.51 [ 1.04, 6.06 ]
Appleton 1999 3/119 2/128 5.7 % 1.61 [ 0.16, 16.56 ]
Yamauchi 2006 24/127 4/82 14.3 % 3.87 [ 1.01, 14.83 ]
Subtotal (99% CI) 705 501 100.0 % 2.43 [ 1.44, 4.12 ]
Total events: 111 (Gabapentin), 28 (Placebo)
Heterogeneity: Chi2 = 1.82, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.36 (P = 0.000013)
3 Fatigue
Anhut 1994 16/163 5/109 27.8 % 2.14 [ 0.59, 7.70 ]
UK Gabapentin 1990 8/61 0/66 2.2 % 18.37 [ 0.44, 758.67 ]
US Gabapentin 1993 24/208 7/98 44.1 % 1.62 [ 0.56, 4.67 ]
Appleton 1999 4/119 2/128 8.9 % 2.15 [ 0.24, 19.54 ]
Yamauchi 2006 1/127 3/82 16.9 % 0.22 [ 0.01, 4.12 ]
Subtotal (99% CI) 678 483 100.0 % 1.95 [ 0.99, 3.82 ]
Total events: 53 (Gabapentin), 17 (Placebo)
Heterogeneity: Chi2 = 6.36, df = 4 (P = 0.17); I2 =37%
Test for overall effect: Z = 2.54 (P = 0.011)
4 Headache
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours gabapentin
(Continued . . . )
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(. . . Continued)
Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Anhut 1994 5/163 8/109 20.3 % 0.42 [ 0.10, 1.75 ]
Sivenius 1991 1/27 2/18 5.1 % 0.33 [ 0.02, 7.08 ]
UK Gabapentin 1990 0/61 6/66 13.3 % 0.08 [ 0.00, 3.55 ]
US Gabapentin 1993 30/208 12/98 34.6 % 1.18 [ 0.52, 2.68 ]
Appleton 1999 6/119 8/128 16.4 % 0.81 [ 0.21, 3.12 ]
Yamauchi 2006 8/127 4/82 10.3 % 1.29 [ 0.28, 5.99 ]
Subtotal (99% CI) 705 501 100.0 % 0.79 [ 0.46, 1.35 ]
Total events: 50 (Gabapentin), 40 (Placebo)
Heterogeneity: Chi2 = 6.50, df = 5 (P = 0.26); I2 =23%
Test for overall effect: Z = 1.14 (P = 0.25)
5 Nausea
Anhut 1994 9/163 10/109 35.1 % 0.60 [ 0.19, 1.88 ]
US Gabapentin 1993 18/208 9/98 35.9 % 0.94 [ 0.35, 2.57 ]
Appleton 1999 10/119 9/128 25.4 % 1.20 [ 0.38, 3.73 ]
Yamauchi 2006 4/127 1/82 3.6 % 2.58 [ 0.15, 44.95 ]
Subtotal (99% CI) 617 417 100.0 % 0.95 [ 0.52, 1.73 ]
Total events: 41 (Gabapentin), 29 (Placebo)
Heterogeneity: Chi2 = 2.14, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
6 Somnolence
Yamauchi 2006 4/127 1/82 2.8 % 2.58 [ 0.15, 44.95 ]
Anhut 1994 31/163 13/109 35.3 % 1.59 [ 0.72, 3.51 ]
Appleton 1999 10/119 6/128 13.1 % 1.79 [ 0.49, 6.51 ]
Sivenius 1991 6/27 2/18 5.4 % 2.00 [ 0.28, 14.08 ]
UK Gabapentin 1990 9/61 3/66 6.5 % 3.25 [ 0.62, 16.99 ]
US Gabapentin 1993 51/208 12/98 36.9 % 2.00 [ 0.93, 4.30 ]
Subtotal (99% CI) 705 501 100.0 % 1.93 [ 1.22, 3.06 ]
Total events: 111 (Gabapentin), 37 (Placebo)
Heterogeneity: Chi2 = 1.15, df = 5 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 3.67 (P = 0.00025)
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours gabapentin
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A D D I T I O N A L T A B L E S
Table 1. Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, intention-to-
treat
Dose % Responders (95% CI) % Difference (95% CI) compared to placebo
0 mg (placebo) 9.7 (7.2 to 12.9)
600 mg 13.6 (11.4 to 16.1) 3.9 (1.6 to 6.2)
900 mg 16.0 (13.7 to 18.6) 6.3 (2.8 to 9.8)
1200 mg 18.7 (15.8 to 22.1) 9.0 (4.4 to 13.7)
1800 mg 25.3 (19.3 to 32.3) 15.5 (8.5 to 22.5)
CI: confidence interval.
Table 2. Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, best-case
Dose Responders % (95% CI) % Difference (95% CI) compared to placebo
0 mg (placebo) 10.9 (8.1 to 14.5)
600 mg 17.2 (14.6 to 20.2) 6.3 (3.9 to 8.8)
900 mg 21.4 (18.5 to 24.6) 10.5 (6.8 to 14.2)
1200 mg 26.2 (22.4 to 30.4) 15.3 (10.3 to 20.0)
1800 mg 37.6 (30.0 to 46.0) 26.7 (19.3 to 34.2)
CI: confidence interval.
Table 3. Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, worst-case
Dose Responders % (95% CI) % Difference (95% CI) compared to placebo
0 mg (placebo) 13.8 (10.4 to 18.2)
600 mg 16.4 (13.8 to 19.2) 2.5 (-0.3 to 5.3)
900 mg 17.8 (15.3 to 20.5) 3.9 (-0.3 to 8.1)
1200 mg 19.2 (16.2 to 22.7) 5.4 (-0.2 to 11.0)
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Table 3. Estimated percentage responders and percentage difference compared to placebo per gabapentin dose, worst-case
(Continued)
1800 mg 22.5 (17.1 to 29.0) 8.6 (0.3 to 17.0)
CI: confidence interval.
Table 4. Adverse effects Fisher 2001
Adverse ef-
fect
Slow initia-
tion (day 2)
% Rapid initia-
tion (day 2)
% Slow initiation
(day 7)
% Rapid initiation
(day 7)
%
Fatigue 9/280 3.2 12/294 4.1 19/274 6.9 22/294 7.5
Dizziness 18/280 6.4 31/294 10.5 45/276 16.3 59/293 19.1
Somno-
lence
13/280 4.6 16/294 5.4 27/275 9.8 31/293 10.6
Ataxia 2/280 0.7 4/294 1.4 9/275 3.3 9/294 3.1
A P P E N D I C E S
Appendix 1. Cochrane Register of Studies search strategy
1. (gabapentin or Neurontin) AND INREGISTER AND >03/11/2016:CRSCREATED
2. gabapentin or Neurontin AND CENTRAL:TARGET
3. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
4. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
5. epilep* OR seizure* OR convuls* AND CENTRAL:TARGET
6. #3 OR #4 OR #5 AND CENTRAL:TARGET
7. #2 AND #6 AND CENTRAL:TARGET
8. (monotherap* NOT (adjunct* OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*)):TI ANDCENTRAL:
TARGET
9. #7 NOT #8 AND CENTRAL:TARGET
10. >03/11/2016:CRSINCENTRAL AND CENTRAL:TARGET
11. #9 AND #10 AND CENTRAL:TARGET
12. #1 OR #11
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Appendix 2. MEDLINE (Ovid) search strategy
This strategy was based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre 2011).
1. (gabapentin or neurontin).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$)).ti.
16. 14 not 15
17. remove duplicates from 16
18. limit 17 to ed=20161103-20180320
19. 17 not (1$ or 2$).ed.
20. 19 and (2016$ or 2017$ or 2018$).dt.
21. 18 or 20
Appendix 3. ClinicalTrials.gov search strategy
Epilepsies, Partial | Gabapentin | First posted on or after 11/03/2016
Appendix 4. ICTRP search strategy
Condition: epilepsy
Intervention: gabapentin
Date of registration between 11/03/2016 and 20/03/2018
WH A T ’ S N E W
Date Event Description
20 March 2018 New citation required but conclusions have not changed Conclusions are unchanged.
20 March 2018 New search has been performed Searches updated 20 March 2018; one new study has
been included
The term ’partial’ has been replaced by ’focal’, in accor-
dance with the most recent classification of epilepsies
of the International League Against Epilepsy (Scheffer
2017).
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H I S T O R Y
Protocol first published: Issue 1, 1999
Review first published: Issue 1, 1999
Date Event Description
14 May 2013 New search has been performed Searches updated 14 May 2013.
14 May 2013 New citation required but conclusions have not
changed
Six new studies included. Conclusions remain un-
changed.
10 September 2008 Amended Converted to new review format.
1 July 2007 New search has been performed We re-ran our searches on 1 July 2007. One potential
new study has been identified - this has been added to
the ’Studies awaiting classification’ section and will be
assessed for inclusion at a later date
C O N T R I B U T I O N S O F A U T H O R S
MP independently assessed trials for inclusion in the present update.
SAB and J Weston carried out the previous update of this review.
JLH and JW completed the dose-regression analysis.
AGM and JLH developed the original protocol.
D E C L A R A T I O N S O F I N T E R E S T
SB: none known.
JW: none known.
MP: none known.
JLH: none known.
AGM: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in
Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for
Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The term ’partial’ has been replaced by ’focal’, in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (Scheffer 2017).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Amines [∗therapeutic use]; Anticonvulsants [∗therapeutic use]; Cyclohexanecarboxylic Acids [∗therapeutic use]; Drug Resistance; Drug
Therapy, Combination [methods]; Epilepsies, Partial [∗drug therapy]; Gabapentin; Treatment Failure; gamma-Aminobutyric Acid
[∗therapeutic use]
MeSH check words
Adult; Child; Humans
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